Bookmark and Share
BioAssay: AID 488987

SAR Analysis for the identification of Selective Antagonists of ERK1/2 Activity in GPR35-Overexpressing U2OS Cells - Set 2

The aim of this assay was to characterize downstream ERK phosphorylation activity of compounds originally identified in "Image-based HTS for Selective Antagonists of GPR35" (AID 2058). Componds were either acquired from commercial sources or synthesized by the Sanford-Burnham Center for Chemical Genomics. ..more
_
   
 Tested Compounds
 Tested Compounds
All(5)
 
 
Active(4)
 
 
Inactive(1)
 
 
 Tested Substances
 Tested Substances
All(5)
 
 
Active(4)
 
 
Inactive(1)
 
 
AID: 488987
Data Source: Burnham Center for Chemical Genomics (SBCCG-A511-GPR35-Antagonist-pERK-DryPowder-Assay-2)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2010-11-03
Hold-until Date: 2011-05-01
Modify Date: 2011-05-03

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 4
Related Experiments
Show more
AIDNameTypeProbeComment
2058Image-Based HTS for Selective Antagonists of GPR35Confirmatory depositor-specified cross reference
2079Summary of Image-based HTS for Selective Antagonists of GPR35Summary3 depositor-specified cross reference
2397SAR Analysis of Selective Antagonists of GPR55 using an Image-Based AssayConfirmatory same project related to Summary assay
2480SAR analysis of Antagonists of the GPR35 Receptor using an Image-Based Assay - Set 2Confirmatory same project related to Summary assay
463201SAR Analysis using an Image-based Vasopressin Agonist Counter Assay for the Identification of Selective Antagonists of the GPR35 ReceptorOther same project related to Summary assay
463202SAR Analysis using an Image-based Vasopressin Antagonist Counter Assay for the Identification of Selective Antagonists of the GPR35 ReceptorOther same project related to Summary assay
463217SAR Analysis for the identification of Selective Antagonists of ERK1/2 Activity in GPR35-Overexpressing U2OS CellsConfirmatory same project related to Summary assay
463227SAR analysis of Antagonists of the GPR35 Receptor using an Image-Based Assay - Set 5Confirmatory same project related to Summary assay
463228SAR Analysis of Selective Antagonists of GPR55 using an Image-Based Assay - Set 3Confirmatory same project related to Summary assay
Description:
Data Source: Dr. Mary Abood
Source Affiliation: Temple University
Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1X01MH085708-01
Assay Provider: Dr. Lawrence Barak, Duke University

The aim of this assay was to characterize downstream ERK phosphorylation activity of compounds originally identified in "Image-based HTS for Selective Antagonists of GPR35" (AID 2058). Componds were either acquired from commercial sources or synthesized by the Sanford-Burnham Center for Chemical Genomics.

This In-Cell Western assay utilizes a cell line permanently expressing a beta-arrestin GFP biosensor and human GPR35 receptor. Upon agonist-mediated GPCR activation, ERK1/2 phosphorylation occurs as measured by pERK1/2 antibodies.
Protocol
Assay Materials:
1) 96-well plates (FALCON 353075)
2) U2OS (Human Osteosarcoma) cell line stably expressing the Beta-arrestin GFP and human GPR35 receptor
3) Culture Media: DMEM with 10% Fetal Bovine Serum and selection antibiotics - 200ug/ml G418 and 100ug/ml Zeocin
4) EC80 concentration of Agonist: 10 uM Zaprinast
5) DMSO solution
6) Test compounds Working Solution: 10mM Stock in 100% DMSO, diluted in assay buffer (HBSS Cellgro #21-023-CV)
7) Fixative Solution: 4% Paraformaldehyde (PFA) diluted in PBS
8) Permeabilization Solution: 0.1% Triton X-100 in PBS
9) Primary phosphor-ERK1/2 antibody (Cell Signaling Technology, diluted 1:100)
10) Goat anti-rabbit 800CW secondary antibody diluted 1:800 in Licor blocking buffer together with Sapphire700 (diluted 1:1000) and DRAQ5 (diluted 1:2000) for normalization purpose
Assay Procedure:
1) Cells were grown to confluence in 96-well plates and serum-starved overnight prior to assay.
2) Prior to drug treatment cells were washed once with HBSS at room temperature.
3) Compounds were added at varying dose response concentrations together with the agonist (10uM Zaprinast) to compound and negative control wells.
4) DMSO was added to all wells to achieve a final concentration of 0.1%.
5) Plates were incubated for 15 minutes at room temperature.
6) Media was aspirated from all wells.
7) Fixative solution was added to each well for a final concentration of 4% PFA and plates were incubated for 60 minutes at room temperature.
8) Fixative was aspirated and cells were permeabilized with 0.1% Trion X-100 in PBS for 5 washes at 10 minutes per wash.
9) LI-COR blocking buffer was added and samples were shaken on a rotator for 1 hour.
10) Primary antibodies were applied overnight at 4 degree C with rotation, followed by washing 4 times for 5 minutes each in PBS+ 0.1% Tween-20 with gentle shaking at room temperature.
11) Cells were incubated with secondary antibodies for 2 hours at room temperature. Sapphire700 and DRAQ5 solutions were added together with the secondary antibodies for normalization. Plates were protected from light.
12) Plates were washed 4 times for 5 minutes each in PBS + 0.1% Tween-20 with gentle shaking at room temperature, and were protected from light.
13) Plates were dried and scanned using a LI-COR Odyssey Infrared Imager.
14) IC50 values were calculated employing a sigmoidal dose-response equation through non-linear regression in Prism 4.0 software.
Comment
Compounds with an IC50 <10uM were considered active.
To simplify the distinction between the actives of the primary screen and of the confirmatory dose response, a tiered activity scoring system was devised to take into consideration compound efficacy and potential interference with the assay. The outline of the scoring system utilized for the screen is as follows:
1) First tier (0-40 range) is reserved for primary and confirmation screening data and is not applicable in this assay.
2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable in this assay.
3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues
a. Inactive compounds of the confirmatory stage are assigned a score value equal 81.
b. The score is linearly correlated with a compound potency and, in addition, provides a measure of the likelihood that the compound is not an artifact based on the available information.
c. Summary equation that takes into account the items discussed above is
Score = 82 + 3*(pIC50 - 3),
where pIC50 is a negative log(10) of the IC50 value expressed in mole/L concentration units. This equation results in the Score values above 85 for compounds that demonstrate high potency and predictable behavior. Compounds that are inactive in the assay or whose concentration-dependent behavior are likely to be an artifact of that assay will generally have lower Score values.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Cell Type: U-2 OS
From ChEMBL:
Assay Type: Functional
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1IC50_QualifierThis qualifier is to be used with the next TID, IC50. If qualifier is "=", IC50 result equals to the value in that column; if qualifier is ">", IC50 result is greater than that value.String
2IC50*IC50 value determined using sigmoidal dose response equationFloatμM
3Std.Err(IC50)Standard Error of IC50 valueFloatμM
4%Activity at 32 uM_1 (32μM**)Percent Activity at the tested concentration - first replicateFloat%
5%Activity at 10 uM_1 (10μM**)Percent Activity at the tested concentration - first replicateFloat%
6%Activity at 1 uM_1 (1μM**)Percent Activity at the tested concentration - first replicateFloat%
7%Activity at 0.1 uM_1 (0.1μM**)Percent Activity at the tested concentration - first replicateFloat%
8%Activity at 0.01 uM_1 (0.01μM**)Percent Activity at the tested concentration - first replicateFloat%
9%Activity at 0.001 uM_1 (0.001μM**)StaPercent Activity at the tested concentration - first replicateFloat%
10%Activity at 32 uM_2 (32μM**)Percent Activity at the tested concentration - second replicateFloat%
11%Activity at 10 uM_2 (10μM**)Percent Activity at the tested concentration - second replicateFloat%
12%Activity at 1 uM_2 (1μM**)Percent Activity at the tested concentration - second replicateFloat%
13%Activity at 0.1 uM_2 (0.1μM**)Percent Activity at the tested concentration - second replicateFloat%
14%Activity at 0.01 uM_2 (0.01μM**)Percent Activity at the tested concentration - second replicateFloat%
15%Activity at 0.001 uM_2 (0.001μM**)Percent Activity at the tested concentration - second replicateFloat%
16%Activity at 32 uM_3 (32μM**)Percent Activity at the tested concentration - third replicateFloat%
17%Activity at 10 uM_3 (10μM**)Percent Activity at the tested concentration - third replicateFloat%
18%Activity at 1 uM_3 (1μM**)Percent Activity at the tested concentration - third replicateFloat%
19%Activity at 0.1 uM_3 (0.1μM**)Percent Activity at the tested concentration - third replicateFloat%
20%Activity at 0.01 uM_3 (0.01μM**)Percent Activity at the tested concentration - third replicateFloat%
21%Activity at 0.001 uM_3 (0.001μM**)Percent Activity at the tested concentration - third replicateFloat%
22%Activity at 32 uM_4 (32μM**)Percent Activity at the tested concentration - fourth replicateFloat%
23%Activity at 10 uM_4 (10μM**)Percent Activity at the tested concentration - fourth replicateFloat%
24%Activity at 1 uM_4 (1μM**)Percent Activity at the tested concentration - fourth replicateFloat%
25%Activity at 0.1 uM_4 (0.1μM**)Percent Activity at the tested concentration - fourth replicateFloat%
26%Activity at 0.01 uM_4 (0.01μM**)Percent Activity at the tested concentration - fourth replicateFloat%
27%Activity at 0.001 uM_4 (0.001μM**)Percent Activity at the tested concentration - fourth replicateFloat%
28%Activity at 32 uM_5 (32μM**)Percent Activity at the tested concentration - fifth replicateFloat%
29%Activity at 10 uM_5 (10μM**)Percent Activity at the tested concentration - fifth replicateFloat%
30%Activity at 1 uM_5 (1μM**)Percent Activity at the tested concentration - fifth replicateFloat%
31%Activity at 0.1 uM_5 (0.1μM**)Percent Activity at the tested concentration - fifth replicateFloat%
32%Activity at 0.01 uM_5 (0.01μM**)Percent Activity at the tested concentration - fifth replicateFloat%
33%Activity at 0.001 uM_5 (0.001μM**)Percent Activity at the tested concentration - fifth replicateFloat%
34%Activity at 32 uM_6 (32μM**)Percent Activity at the tested concentration - sixth replicateFloat%
35%Activity at 10 uM_6 (10μM**)Percent Activity at the tested concentration - sixth replicateFloat%
36%Activity at 1 uM_6 (1μM**)Percent Activity at the tested concentration - sixth replicateFloat%
37%Activity at 0.1 uM_6 (0.1μM**)Percent Activity at the tested concentration - sixth replicateFloat%
38%Activity at 0.01 uM_6 (0.01μM**)Percent Activity at the tested concentration - sixth replicateFloat%
39%Activity at 0.001 uM_6 (0.001μM**)Percent Activity at the tested concentration - sixth replicateFloat%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1X01MH085708-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: